Cargando…

Effects of Glucagon-Like Peptide-1 Analogue and Fibroblast Growth Factor 21 Combination on the Atherosclerosis-Related Process in a Type 2 Diabetes Mouse Model

BACKGROUND: Glucagon-like peptide-1 (GLP-1) analogues regulate glucose homeostasis and have anti-inflammatory properties, but cause gastrointestinal side effects. The fibroblast growth factor 21 (FGF21) is a hormonal regulator of lipid and glucose metabolism that has poor pharmacokinetic properties,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Jin Hee, Lee, Gha Young, Maeng, Hyo Jin, Kim, Hoyoun, Bae, Jae Hyun, Kim, Kyoung Min, Lim, Soo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Endocrine Society 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7937856/ https://www.ncbi.nlm.nih.gov/pubmed/33677937 http://dx.doi.org/10.3803/EnM.2020.781

Ejemplares similares

Effect of Fibroblast Growth Factor 21 on the Development of Atheromatous Plaque and Lipid Metabolic Profiles in an Atherosclerosis-Prone Mouse Model
por: Maeng, Hyo Jin, et al.
Publicado: (2020)

Unlocking the Therapeutic Potential of Glucagon-Like Peptide-1 Analogue and Fibroblast Growth Factor 21 Combination for the Pathogenesis of Atherosclerosis in Type 2 Diabetes
por: Son, Jang Won
Publicado: (2021)

Glucagon-like peptide-1 analogues: An overview
por: Gupta, Vishal
Publicado: (2013)

Role of Fibroblast Growth Factor 21 in Biology of Glucagon
por: Berglund, Eric D., et al.
Publicado: (2013)

Effects of Lobeglitazone, a New Thiazolidinedione, on Osteoblastogenesis and Bone Mineral Density in Mice
por: Kim, Kyoung Min, et al.
Publicado: (2017)

Glucagon-like Peptide-1 Receptor Analogues for the Treatment of Obesity
por: Williams, David M, et al.
Publicado: (2022)

Liver-derived fibroblast growth factor 21 mediates effects of glucagon-like peptide-1 in attenuating hepatic glucose output
por: Liu, Junling, et al.
Publicado: (2019)

Fibroblast Growth Factor 21 Mediates Specific Glucagon Actions
por: Habegger, Kirk M., et al.
Publicado: (2013)

Effects of Glucagon-Like-Peptide-1 Analogue Treatment in Genetic Obesity
por: Welling, Mila Sofie, et al.
Publicado: (2021)

Pharmacokinetics of Glepaglutide, A Long-Acting Glucagon-Like Peptide-2 Analogue: A Study in Healthy Subjects
por: Agersnap, Mikkel Askjær, et al.
Publicado: (2022)

Expression of Glucagon-Like Peptide 1 Receptor during Osteogenic Differentiation of Adipose-Derived Stem Cells
por: Jeon, Yun Kyung, et al.
Publicado: (2014)

Investigating the Glucagon Receptor and Glucagon-Like Peptide 1 Receptor Activity of Oxyntomodulin-Like Analogues in Male Wistar Rats
por: Price, Samantha L., et al.
Publicado: (2015)

The Glucagon-Like Peptide-1 Analogue Liraglutide Reduces Seizures Susceptibility, Cognition Dysfunction and Neuronal Apoptosis in a Mouse Model of Dravet Syndrome
por: Liu, Shenhai, et al.
Publicado: (2020)

Comparison of Two DXA Systems, Hologic Horizon W and GE Lunar Prodigy, for Assessing Body Composition in Healthy Korean Adults
por: Park, Seung Shin, et al.
Publicado: (2021)

Glucagon-Like Peptide 1 Receptor Agonists, Carotid Atherosclerosis, and Cardiovascular Outcomes
por: Marquis-Gravel, Guillaume, et al.
Publicado: (2021)

Fibroblast Growth Factor 21 Mimetics for Treating Atherosclerosis
por: Kwok, Kelvin H. M., et al.
Publicado: (2017)

Sex Modifies the Association of Fibroblast Growth Factor 21 With Subclinical Carotid Atherosclerosis
por: Chee, Yingjie, et al.
Publicado: (2021)

Glucagon-like peptide analogues for type 2 diabetes mellitus: systematic review and meta-analysis
por: Shyangdan, Deepson S, et al.
Publicado: (2010)

Glucagon-Like Peptide-2 Analogue ZP1849 Augments Colonic Anastomotic Wound Healing
por: Kjaer, Marie, et al.
Publicado: (2020)

Can glucagon-like peptide-1 (GLP-1) analogues make neuroprotection a reality?
por: Basalay, Maryna V., et al.
Publicado: (2020)

Effects of glucagon‐like peptide‐1 analogue treatment in genetic obesity: A case series
por: Welling, Mila S., et al.
Publicado: (2021)

Functional and structural characteristics of anticancer peptide Pep27 analogues
por: Lee, Dong Gun, et al.
Publicado: (2005)

Antagonistic interaction between central glucagon-like Peptide-1 and oxytocin on diet-induced obesity mice
por: Lee, Jeonghoon, et al.
Publicado: (2020)

Fibroblast Growth Factor 21 Protects against Atherosclerosis via Fine-Tuning the Multiorgan Crosstalk
por: Jin, Leigang, et al.
Publicado: (2016)

The therapeutic potential of a venomous lizard: the use of glucagon-like peptide-1 analogues in the critically ill
por: Deane, Adam M, et al.
Publicado: (2010)

The Glucagon-Like Peptide 1 Analogue, Exendin-4, Attenuates the Rewarding Properties of Psychostimulant Drugs in Mice
por: Egecioglu, Emil, et al.
Publicado: (2013)

Glucagon-like peptide-2 analogues for Crohn’s disease patients with short bowel syndrome and intestinal failure
por: Pizzoferrato, Marco, et al.
Publicado: (2022)

Medicinal Plants Qua Glucagon-Like Peptide-1 Secretagogue via Intestinal Nutrient Sensors
por: Kim, Ki-Suk, et al.
Publicado: (2015)

A Peptide Analogue of Selectin Ligands Attenuated Atherosclerosis by Inhibiting Monocyte Activation
por: Ye, Zhishuai, et al.
Publicado: (2019)

Computational Peptide Design Cotargeting Glucagon and Glucagon-like Peptide-1 Receptors
por: Vishnoi, Shubham, et al.
Publicado: (2023)

Effect of the Glucagon‐like Peptide‐1 Analogue Exenatide Extended Release in Cats with Newly Diagnosed Diabetes Mellitus
por: Riederer, A., et al.
Publicado: (2016)

Glucagon-like peptide-1 analogue exendin-4 modulates serotonin transporter expression in intestinal epithelial cells
por: Cui, Xiufang, et al.
Publicado: (2020)

Potential Roles of Glucagon-Like Peptide-1 and Its Analogues in Dementia Targeting Impaired Insulin Secretion and Neurodegeneration
por: Mehan, Sidharth, et al.
Publicado: (2022)

THU294 Glucagon Like Peptide-1 Analogue Therapy In Obese Patients With Cystic Fibrosis Related Diabetes
por: Reddy Ankireddypalli, Anvitha, et al.
Publicado: (2023)

Transcriptional Regulation of Fibroblast Growth Factor 21 Expression
por: Bae, Kwi-Hyun, et al.
Publicado: (2014)

Correlations between Glucagon Stimulated C-peptide Levels and Microvascular Complications in Type 2 Diabetes Patients
por: Yoon, Hye-Jin, et al.
Publicado: (2012)

25-Hydroxycholesterol-Induced Oxiapoptophagy in L929 Mouse Fibroblast Cell Line
por: You, Jae-Seek, et al.
Publicado: (2021)

Polymer-Based Delivery of Glucagon-Like Peptide-1 for the Treatment of Diabetes
por: Kim, Pyung-Hwan, et al.
Publicado: (2012)

Glucagon-like peptide-1 analog liraglutide leads to multiple metabolic alterations in diet-induced obese mice
por: Park, Seokjae, et al.
Publicado: (2022)

Oxyntomodulin analogue increases energy expenditure via the glucagon receptor
por: Scott, R., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_avftjvt8jj066v7o3ctsckgikk